Equities researchers at Guggenheim started coverage on shares of Clovis Oncology (NASDAQ:CLVS) in a research report issued to clients and investors on Monday, The Fly reports. The firm set a “buy” rating on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the stock. Gabelli restated a “buy” rating on shares of Clovis Oncology in a research report on Monday, July 16th. Royal Bank of Canada restated a “buy” rating and issued a $73.00 price target on shares of Clovis Oncology in a research report on Tuesday, June 12th. Cann restated a “hold” rating on shares of Clovis Oncology in a research report on Monday, June 11th. ValuEngine upgraded shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 2nd. Finally, Zacks Investment Research cut shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the stock. Clovis Oncology currently has a consensus rating of “Buy” and an average target price of $79.65.

CLVS stock traded up $0.46 during trading on Monday, reaching $32.23. 1,000,278 shares of the company were exchanged, compared to its average volume of 1,168,100. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -6.29 and a beta of 1.01. Clovis Oncology has a twelve month low of $31.19 and a twelve month high of $86.26. The company has a debt-to-equity ratio of 1.84, a current ratio of 10.03 and a quick ratio of 9.21.

Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.38) by ($0.56). Clovis Oncology had a negative return on equity of 94.28% and a negative net margin of 382.83%. The company had revenue of $23.76 million for the quarter, compared to analyst estimates of $22.44 million. During the same quarter in the prior year, the company earned ($1.29) earnings per share. Clovis Oncology’s revenue for the quarter was up 62.5% compared to the same quarter last year. equities research analysts anticipate that Clovis Oncology will post -6.77 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of CLVS. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Clovis Oncology by 5,000.0% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,550 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 2,500 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Clovis Oncology during the first quarter worth $146,000. Advisors Asset Management Inc. increased its position in shares of Clovis Oncology by 1,017.5% during the second quarter. Advisors Asset Management Inc. now owns 56,668 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 51,597 shares during the period. Summit Trail Advisors LLC increased its position in shares of Clovis Oncology by 4,092.7% during the first quarter. Summit Trail Advisors LLC now owns 249,258 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 243,313 shares during the period. Finally, LPL Financial LLC increased its position in shares of Clovis Oncology by 66.6% during the first quarter. LPL Financial LLC now owns 5,461 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 2,184 shares during the period.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

The Fly

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.